Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
BusinessWeek May 9, 2005 John Carey	Dr. Francis S. Collins: On The Trail Of Disease Genes Collins is leading the search for DNA variations that can result in illnesses.
The Motley Fool August 17, 2007 Brian Orelli	FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions.
BusinessWeek June 13, 2005 John Carey	The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
American Journal of Nursing October 2009	Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response.
The Motley Fool June 11, 2010 Brian Orelli	Pfizer and Bristol Coagulate Against Clots Let's see how apixaban does against warfarin before we break out the "blockbuster" stamp.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
Nurse Practitioner August 2009 Linda A. Howe	Pharmacogenomics and management of cardiovascular disease Prior to the completion of the Human Genome Project in 2003, individual responses to medications were usually termed idiosyncrasies. Ethnic differences were not usually seen as genetic variants, as is the case today.
The Motley Fool February 4, 2010 Brian Orelli	Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct.
The Motley Fool December 15, 2008 Brian Orelli	Medicine Gets a Little More Personal Genetic testing and personalized medicine are still in their infancy, but it's an emerging industry that should be huge in the long run. Which companies stand to benefit from it?
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
Chemistry World February 25, 2015 Rebecca Trager	US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests.
Salon.com May 1, 2000 Arthur Allen	Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
Wired November 2002 David Ewing Duncan	DNA as Destiny DNA is the book of life. It's also the book of death. In the future we'll all be read cover to cover. Here's what it's like to take the world's first top-to-bottom gene scan.
The Motley Fool February 23, 2010 Brian Orelli	Triple-Teaming Cancer for Fun and Profit Pfizer, Merck and Eli Lilly set up a nonprofit, but there may be an ulterior motive.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
BusinessWeek February 20, 2006 Gene G. Marcial	Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it.
The Motley Fool November 30, 2011 Brian Orelli	Drugmakers Bleeding Out That's not what blood thinners are supposed to do.
Fast Company November 2009 David H. Freedman	The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens.
BusinessWeek November 7, 2005 Catherine Arnst	How Likely Are You To Get Sick? A new DNA database could gauge your risk for disease.
HHMI Bulletin May 2011 Elise Lamar	Sequencing Adrenal Tumors A global team of researchers showed that potassium channel mutations promote tumor formation and hypertension.
Bio-IT World September 9, 2002 Malorye Branca	The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems.
Pharmaceutical Executive September 1, 2010	The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development.
HHMI Bulletin Nov 2010	Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	Guiding a Revolution in Science Francis Collins led the genomic revolution as director of the International Human Genome Project and director of the National Human Genome Research Institute (NHGRI) at the NIH from 1993 to 2008.
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
HHMI Bulletin Aug 2011	Seeing is Believing Today, researchers are finding clever ways to deliver long-lasting, healthy genes without triggering a serious immune response.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
BusinessWeek May 9, 2005	A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon.
The Motley Fool November 15, 2010 Brian Orelli	A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind.
BusinessWeek October 1, 2009	Stalking the Future J&J lost patent protection on epilepsy and schizophrenia drugs worth $7 billion last year. These new drugs, if cleared by the FDA, could help offset the damage.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
IEEE Spectrum March 2013 Eliza Strickland	The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine
The Motley Fool April 26, 2011 Luke Timmerman	FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex?
Scientific American June 2009 Melinda Wenner	Genetic Copy Variations and Disease A new sense for how variable numbers of genes cause disease.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
Pharmaceutical Executive February 1, 2011 Jill Wechsler	The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
PC World February 1, 2002 Kuriko Miyake	Olympus Unveils DNA Computer Rather than relying on a microprocessor, computer runs on reactions between fragments of DNA...
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
Wired November 17, 2007 Thomas Goetz	23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.